ALLO-715, an investigational donor-derived CAR T-cell therapy by Allogene Therapeutics, has a manageable safety profile and promising preliminary efficacy results in people with relapsed or refractory multiple myeloma, a Phase 1 clinical trial has shown. The results will be presented at the 62nd Annual Meeting of the American Society of Hematology, taking place virtually in December. The presentation is titled “An Allogeneic First-in-Human Study of the Anti-Bcma ALLO-715 and the Anti-CD52 ALLO-647 in Relapsed/Refractory Multiple…
You must be logged in to read/download the full post.
The post Allogene to Present Positive Phase 1 Data for Investigational CAR T-cell Therapy ALLO-715 appeared first on BioNewsFeeds.